Female Reproductive & Breast

Lichen sclerosus: diagnosis and management

Clinical Overview and When to Suspect Lichen Sclerosus

— Postmenopausal woman with vulvar pruritus (especially nocturnal), dyspareunia, dysuria, or anal fissuring/painful defecation

— Prepubertal girl with "sexual abuse" mimic — purpura, fissures, dysuria, constipation from painful stooling

— Refractory "yeast infection" despite repeated antifungals

— Loss of normal vulvar architecture noted incidentally on Pap/pelvic exam

— Phimosis in adult or boy without prior history

Board pearl: A postmenopausal woman with persistent vulvar itch, "figure-8" or hourglass white plaques encircling vulva and perianal area, and a history of Hashimoto thyroiditis → think LS first, not candidiasis. Empiric antifungals delay diagnosis and allow scarring; early ultrapotent topical steroids prevent architectural loss and reduce malignant transformation risk.

Lichen sclerosus (LS) is a chronic, inflammatory, lymphocyte-mediated dermatosis with a striking predilection for the anogenital skin, causing progressive thinning, hypopigmentation, scarring, and architectural distortion.

Epidemiology — bimodal female peaks: prepubertal girls (often 4–7 yr) and postmenopausal women (50s–70s); ~1 in 60–80 women affected, though widely underdiagnosed. Men: balanitis xerotica obliterans variant on glans/foreskin.

Etiology — autoimmune-leaning: associated with thyroid disease (Hashimoto), vitiligo, alopecia areata, pernicious anemia, type 1 DM, and morphea. Koebner phenomenon (trauma/incontinence) triggers lesions. HLA-DQ7 association.

When to suspect in clinic:

Why Step 3 cares — LS is a chronic outpatient diagnosis managed longitudinally by family medicine/gynecology, requires lifetime surveillance for vulvar squamous cell carcinoma (lifetime risk ~4–5%), and is repeatedly missed or mismanaged as candidiasis, atrophic vaginitis, or abuse.

Presentation Patterns and Key History

— Urinary — dysuria from periurethral involvement, splayed/deflected stream, urge from skin splitting

— Defecatory — painful defecation, anal fissures, constipation in children (key red flag — child withholds stool due to pain)

— Sexual — introital narrowing → superficial dyspareunia, post-coital bleeding, apareunia in advanced disease

— Bleeding/bruising — ecchymoses and blood blisters from minor friction (often mistaken for trauma/abuse)

— Duration and pattern of itch; nocturnal awakening

— Prior empiric antifungals, OTC steroid creams, "estrogen creams" with partial/no response

— Sexual function, partner symptoms (rule out STI/contact)

— Personal or family autoimmune disease (thyroid #1, vitiligo, alopecia areata, T1DM, celiac)

— Incontinence, chronic moisture, tight clothing (Koebner triggers)

— In children: stool withholding, encopresis, behavioral changes — always document non-abuse findings carefully

— In men: phimosis, recurrent balanitis, narrowed meatus, weak stream

Key distinction: LS itches and scars; lichen simplex chronicus itches and thickens (lichenifies) without architectural loss; atrophic vaginitis burns and involves the vagina (LS spares the vagina).

Step 3 management: When a postmenopausal patient reports >6 weeks of vulvar itch unresponsive to antifungals or topical estrogen, schedule a dedicated vulvar exam visit with good lighting and a hand mirror — don't keep refilling miconazole.

Core symptom triad — pruritus, soreness, dyspareunia. Pruritus is the hallmark, often worse at night and severe enough to disturb sleep.

Additional symptom clusters:

History points to elicit:

Natural history — relapsing-remitting; spontaneous remission rare in adults; some prepubertal cases improve at puberty but ~⅔ persist into adulthood and need follow-up.

Physical Exam Findings (and Vulvoscopic Assessment)

— Porcelain-white, atrophic, "cigarette-paper" or wrinkled (cellophane) plaques

— Figure-8 / hourglass / keyhole distribution encircling vulva and anus

— Ecchymoses, purpura, blood blisters, fissures within white plaques

— Hyperkeratosis, erosions, telangiectasias

— Waxy sheen and loss of normal pigmentation

— Loss/resorption of labia minora (fuses to labia majora)

— Clitoral phimosis — burying of clitoris under fused prepuce → can develop pseudocyst/keratin pearls

— Introital stenosis — narrowed vaginal opening, posterior fourchette tearing

— Midline fissures at fourchette and perianally (Y or keyhole pattern)

Board pearl: Architectural change (labial resorption, clitoral phimosis, introital stenosis) on exam = LS until proven otherwise; atrophic vaginitis does not destroy architecture, it just thins and reddens.

Key distinction: Vaginal involvement and Wickham striae → lichen planus; spared vagina with white scarring → lichen sclerosus.

Setup — supine lithotomy with bright focal light; offer chaperone; use hand mirror to engage patient in identifying lesions; examine entire anogenital region including perianal skin and natal cleft.

Classic skin findings:

Architectural changes (irreversible, drive urgency of diagnosis):

Sites spared — vagina and cervix are NOT involved (critical distinction from lichen planus).

Male exam — whitened, atrophic patches on glans/prepuce, phimosis, meatal stenosis, urethral stricture.

Pediatric exam — perform with parent present, in frog-leg or knee-chest position; figure-8 pallor, purpura, perianal fissures often misread as abuse.

Targeted biopsy site selection — biopsy any thickened, eroded, hyperkeratotic, fixed, or ulcerated area, or any lesion not responding to 3 months of ultrapotent steroid → screening for differentiated VIN or SCC.

Diagnostic Workup — Initial Approach and When to Biopsy

— Diagnostic uncertainty or atypical features

— Failure to respond to 3 months of ultrapotent topical steroid

— Suspicion of neoplasia — hyperkeratosis, fixed erosion, ulcer, induration, pigmented lesion, persistent fissure

— Pre-treatment in adults when feasible (many guidelines now recommend baseline biopsy in adults given malignancy risk and lifelong therapy commitment)

— Children: biopsy generally deferred if classic; do under sedation only if atypical or refractory

— Thinned epidermis with loss of rete ridges

— Hyperkeratosis with follicular plugging

— Subepidermal homogenized/hyalinized collagen band in upper dermis (pathognomonic feel)

— Band-like lymphocytic infiltrate beneath the hyalinized zone

— Basal vacuolar degeneration

— TSH (Hashimoto common)

— Consider CBC, fasting glucose/A1c, ANA if features present; vitamin B12 if pernicious anemia suspected

— Celiac serologies if GI symptoms

Step 3 management: In a postmenopausal woman with classic figure-8 white plaques and itch, start ultrapotent topical steroid empirically and biopsy any area that fails to clear at 3 months — don't delay treatment waiting for path.

Board pearl: Histologic hallmark = hyalinized/homogenized upper dermal collagen with overlying epidermal atrophy and underlying lymphocytic band.

LS is primarily a clinical diagnosis in adult women and prepubertal girls when classic features are present — empiric treatment is acceptable when the picture is textbook.

Vulvar biopsy — indications (memorize for boards):

Biopsy technique — 3–4 mm punch biopsy at edge of an active, non-eroded lesion after local anesthesia; avoid the most atrophic center (low yield) and avoid scarred areas.

Histopathology — classic findings:

Adjunct labs — screen for associated autoimmunity:

Imaging — not routinely needed; reserve for suspected deeper invasion or lymphadenopathy.

Diagnostic Workup — Surveillance Studies and Cancer Screening

— Persistent or new hyperkeratotic plaque

— Ulcer, erosion, or fissure unresponsive to 4–6 weeks of optimal therapy

— Nodule, induration, or fixed lesion

— Pigmented lesion within LS field

— Asymmetric thickening, bleeding, pain disproportionate to exam

— TSH at baseline; repeat if symptomatic

— Skin survey for vitiligo, morphea, alopecia areata

— Screen for urinary/fecal incontinence (Koebner trigger)

— Pelvic floor assessment if dyspareunia persists after skin clearance

Board pearl: Vulvar SCC in LS = HPV-negative, p53-mutated, arising from dVIN — surveillance is clinical exam every 6–12 months for life, not HPV testing.

Key distinction: Usual VIN (uVIN) = HPV-16/18, younger women; differentiated VIN (dVIN) = LS-associated, older women, higher invasion risk.

Why surveillance matters — LS carries a ~4–5% lifetime risk of vulvar squamous cell carcinoma (SCC), typically the HPV-independent, p53-mutated, differentiated VIN (dVIN) pathway. Risk is highest with poorly controlled, undertreated disease — adherent steroid use reduces cancer risk.

Suspicious lesions warranting urgent biopsy:

Vulvoscopy / colposcopy of vulva — useful adjunct in specialty clinics; 5% acetic acid application can highlight acetowhite areas suggestive of VIN; toluidine blue largely abandoned.

HPV testing/cytology — vulvar LS is HPV-independent; routine cervical cytology continues per USPSTF schedule but is not a screen for LS-related vulvar cancer.

Photographic documentation — clinical photography (with consent) at baseline and follow-up is high yield for tracking architectural change and detecting subtle new lesions; document in chart.

Workup for associated conditions at diagnosis:

Men — circumcision specimens should always be sent to pathology when phimosis is treated surgically; LS is the most common cause of acquired adult phimosis and confers SCC risk on the glans.

Treatment Logic and Goals of Care

— Symptom relief (itch, soreness, dyspareunia)

— Restoration of normal skin texture and color

— Prevention of progressive scarring and architectural loss

— Reduction of vulvar SCC risk

— NOT reversal of established architectural changes (set expectation)

— Use plain water or non-soap emollient cleansers; avoid scented soaps, bubble baths, wipes

— Cotton underwear, avoid tight clothing, no panty liners except during menses

— Bland emollient (petrolatum) as barrier, especially after voiding/bathing

— Treat incontinence aggressively — moisture and ammonia drive Koebner flares

— Avoid topical anesthetics with potential sensitizers (benzocaine)

Step 3 management: Frame LS to the patient as a chronic, controllable autoimmune skin condition like eczema — daily/maintenance therapy prevents flares, scarring, and cancer; non-adherence is the leading cause of progression.

Board pearl: Ultrapotent topical steroid is first-line at every age, including prepubertal girls — fear of using clobetasol in children is a classic exam distractor; under-treatment causes more harm than steroid atrophy.

Treatment goals (counsel patient explicitly — boards love this):

Cornerstone therapy = ultrapotent topical corticosteroid (clobetasol propionate 0.05% ointment) — first-line for all ages and both sexes, including children and pregnancy when needed.

Treatment is lifelong — induction → maintenance → surveillance.

General skin care (counseling pearls):

Adjuncts — vaginal estrogen if concurrent genitourinary syndrome of menopause; lubricants for intercourse; pelvic floor PT for vaginismus/dyspareunia post-clearance.

Things to AVOID — topical testosterone (older therapy, abandoned), low-potency steroids alone (inadequate), repeated courses of antifungals "just in case."

Pharmacotherapy — First-Line Regimen

— Ointment preferred over cream — better penetration, fewer preservatives/irritants

— Pea-sized amount (~0.5 g) covers entire vulva; one 30 g tube should last ~12 weeks at induction dosing — if used faster, suspect overuse; if much slower, suspect under-treatment

— Once daily at bedtime × 4 weeks, then

— Alternate nights × 4 weeks, then

— Twice weekly × 4 weeks

— Total induction ~12 weeks, then reassess

— 1–2 times per week clobetasol indefinitely, OR

— Step-down to mid-potency steroid (mometasone, triamcinolone) 1–2x/week

— Proactive maintenance beats reactive (flare-driven) use — reduces relapse and may reduce SCC risk

— Topical calcineurin inhibitors — tacrolimus 0.1% ointment or pimecrolimus 1% — useful when steroid atrophy a concern or in long-term maintenance; black-box warning about theoretical malignancy is largely unsupported but disclose

— Avoid as monotherapy in active disease — less effective than clobetasol

— Intralesional triamcinolone for hyperkeratotic plaques

— Short oral methotrexate, retinoids (acitretin), hydroxychloroquine under specialist care

— Emerging: UVA1 phototherapy, fractional CO₂ laser, PRP — limited evidence, not first-line on boards

— Examine for atrophy, telangiectasia, striae, candidiasis, contact dermatitis at follow-ups

— True steroid atrophy on vulvar skin with appropriate use is uncommon; LS atrophy is often misattributed

Board pearl: Treatment failure most often = under-use, wrong vehicle (cream instead of ointment), or wrong diagnosis — re-examine technique, adherence, and consider biopsy before escalating.

CCS pearl: Order clobetasol 0.05% ointment, 30 g, with refills, schedule follow-up at 3 months, and add TSH to baseline labs.

First-line: clobetasol propionate 0.05% ointment (ultrapotent class I topical steroid).

Induction regimen (typical):

Maintenance:

Second-line / steroid-sparing:

Refractory disease:

Monitoring for steroid effects:

Procedures and Surgical Management

— Suspected or confirmed vulvar SCC / dVIN → wide local excision ± sentinel node, oncology referral

— Symptomatic introital stenosis preventing intercourse or causing recurrent fissures → perineoplasty / Fenton procedure after disease quiescent on medical therapy

— Clitoral phimosis with pseudocyst, keratin pearls, or pain → dorsal slit or excision of fused prepuce

— Labial adhesions causing urinary obstruction

— Male phimosis / urethral stenosis → circumcision (often curative in adult male LS); meatotomy for meatal stenosis; urethroplasty for strictures

— Resume topical clobetasol as soon as wound healed (typically 2–4 weeks)

— Vaginal dilator therapy after introital surgery to prevent re-stenosis

— Pelvic floor PT for dyspareunia

— Fractional CO₂ laser — symptomatic benefit in trials, not proven to alter natural history or reduce cancer risk; not standard of care

— Platelet-rich plasma (PRP) injections — experimental

— High-intensity focused ultrasound — investigational

Key distinction: Surgery for LS is reconstructive or oncologic, not anti-inflammatory — never offer perineoplasty as a substitute for steroid therapy.

Step 3 management: A woman with treated LS who still cannot have intercourse due to a fibrotic, narrow introitus after 6 months of disease control → refer for perineoplasty, then continue clobetasol maintenance postop and add dilator therapy.

Board pearl: Adult-onset acquired phimosis in a man = LS until proven otherwise; send circumcision specimen to pathology to evaluate for dVIN/SCC.

Surgery does NOT treat LS itself — medical therapy controls inflammation; surgery addresses complications and malignancy.

Indications for surgical referral (gynecology, urology, or vulvar specialist):

Timing principle — operate on quiescent, well-controlled disease (≥3 months stable on steroids) to reduce Koebner-driven recurrence.

Postoperative care:

Adjunctive / emerging procedures (know but not first-line):

Pediatric surgery — rarely needed; reserve for labial fusion causing urinary obstruction.

Special Populations — Elderly and Comorbidity Considerations

— Co-prescribe low-dose vaginal estrogen (estradiol tablet, ring, or cream) for GSM features (vaginal dryness, dyspareunia from atrophy) — does not treat LS but addresses concurrent atrophy

— Distinguish: LS = vulvar skin, scarring, white; GSM = vaginal mucosa, thinning, red/pale, no scarring

— Arthritis, vision loss, and obesity can impair patient's ability to apply topical steroid accurately → use hand mirror demonstration, written diagrams, partner or caregiver assistance

— Consider monthly check-ins by phone or portal during induction

— Elderly vulvar skin is already thin — ointment vehicle reduces stinging; counsel on gentle application, not rubbing

— Watch for contact dermatitis from incontinence pads, wipes; switch to plain water + emollient barrier

Board pearl: Elderly woman with vulvar itch and "atrophy" partially responsive to vaginal estrogen — re-examine for LS hiding under GSM; the two coexist frequently and require dual therapy.

Step 3 management: Always check A1c and TSH at LS diagnosis in older adults — both common, both modifiable, both worsen the disease course.

Postmenopausal women are the predominant adult population with LS — superimposed genitourinary syndrome of menopause (GSM) is common and worsens symptoms.

Polypharmacy and adherence:

Frailty and skin fragility:

Renal impairment — topical clobetasol is minimally systemically absorbed; no dose adjustment for CKD. Same for tacrolimus ointment.

Hepatic impairment — topical therapy safe; oral methotrexate/acitretin (rare refractory cases) require dose adjustment and hepatology input.

Diabetes — increases candida superinfection risk during steroid therapy; optimize A1c, treat candida promptly with topical azole, do not stop the clobetasol.

Immunosuppression (transplant, chemotherapy) — LS may flare; calcineurin inhibitors theoretically problematic; favor clobetasol with careful monitoring; lower threshold for biopsy of suspicious areas.

Anticoagulation — biopsy planning: 3 mm punch generally safe on apixaban/warfarin without interruption; hold if larger excision planned per surgical protocol.

Special Populations — Pediatrics, Pregnancy, and Men

— Presents with pruritus, dysuria, painful defecation, constipation, vulvar/perianal bruising or fissures — frequently misdiagnosed as sexual abuse, candidiasis, or pinworms

— Document carefully — LS purpura/fissures are non-abuse findings; involve child protective services only if exam features or history independently suggest abuse

— Treatment: ultrapotent topical steroid (clobetasol 0.05% ointment) is first-line and safe; same induction taper as adults, supervised by parent

— Outcome: ~⅔ of cases persist into adulthood; do not assume puberty cures it — transition follow-up to gynecology

— LS may improve, worsen, or remain stable; pregnancy is not contraindication to clobetasol — topical steroids are pregnancy-compatible (category C historically; minimal systemic absorption)

— Vaginal delivery is not contraindicated unless severe introital stenosis or active fissures threaten obstetric trauma — discuss individualized mode of delivery

— Avoid retinoids (acitretin — teratogenic); methotrexate contraindicated

— Whitened, atrophic glans/prepuce, acquired phimosis, meatal stenosis, urethral stricture

— First-line: clobetasol 0.05% ointment to glans/foreskin daily × 1–3 months; effective in many early cases

— Circumcision is often curative for foreskin-limited disease and is offered when medical therapy fails or phimosis is fixed

— Surveillance for penile SCC required — exam every 6–12 months

Key distinction: Pediatric vulvar bruising in figure-8 distribution with white plaques = LS, not abuse — but always evaluate context; the two are not mutually exclusive.

Board pearl: Pregnant patient with LS → continue clobetasol; do not switch to a less effective agent out of misplaced fetal concern.

Prepubertal girls:

Pregnancy:

Lactation — topical clobetasol to vulva is safe; not applied to breast.

Adolescents — adherence challenging; emphasize discreet self-care, address sexual function questions proactively, screen for depression/body image impact.

Men (balanitis xerotica obliterans):

Complications and Adverse Outcomes

— Labial resorption and fusion — labia minora flatten and merge into majora

— Clitoral phimosis with buried clitoris, keratin pseudocyst, sometimes painful pseudocyst requiring drainage

— Introital stenosis → dyspareunia, apareunia

— Posterior fourchette fissuring with recurrent tearing during intercourse or defecation

— Urethral involvement → splayed stream, urinary retention (rare), recurrent UTI

— Anal stenosis, chronic fissures, painful defecation — especially in children → fecal withholding, encopresis

— Sexual dysfunction: dyspareunia, anorgasmia, loss of clitoral sensation, avoidance

— Depression, anxiety, body image distress — screen at follow-ups (PHQ-2/9, GAD-7)

— Relationship strain — engage partner in counseling when appropriate

— Vulvar SCC (lifetime risk ~4–5%) via differentiated VIN (dVIN) — HPV-independent, p53-driven

— Higher risk with poor adherence, hyperkeratotic disease, prior dVIN

— Penile SCC in men with longstanding untreated LS

— Steroid-induced atrophy, telangiectasia, striae — uncommon with appropriate use on vulvar mucocutaneous skin

— Candidiasis or HSV reactivation under occlusive therapy — treat the infection, do not stop steroid

— Contact dermatitis from ointment vehicle or self-applied "natural" remedies

— Tachyphylaxis — rarely a true issue; usually reflects under-dosing or wrong vehicle

Board pearl: Any non-healing erosion, fixed ulcer, hyperkeratotic nodule, or new pigmented lesion in LS → biopsy immediately to rule out dVIN/SCC; do not "give it another month of steroid."

Step 3 management: Set a shared decision-making conversation at diagnosis covering lifelong therapy, cancer surveillance, and sexual function — document understanding.

Architectural / functional complications:

Sexual and psychological morbidity:

Malignant transformation:

Treatment-related complications:

Secondary infections — superficial bacterial colonization of fissures; staph/strep cellulitis rare but treat promptly.

When to Escalate Care — Referral and Multidisciplinary Triage

— Diagnostic uncertainty or atypical exam

— Failure to respond to 3 months of properly applied ultrapotent steroid

— Architectural distortion causing functional impairment (dyspareunia, apareunia)

— Need for perineoplasty, dorsal slit, or excision of fused tissue

— Pediatric LS — consider pediatric gynecology or pediatric dermatology

— Coexistent extragenital LS, morphea, or other autoimmune skin disease

— Consideration of phototherapy, methotrexate, retinoids

— Biopsy showing dVIN, SCC, or invasive disease

— Suspicious lesion (ulcer, induration, fixed nodule) — refer before biopsy in some systems, or biopsy and refer immediately with results

— Phimosis, meatal stenosis, urethral stricture

— Suspicious penile lesion

— Persistent dyspareunia after skin clearance

— Vaginismus, hypertonic pelvic floor

— Body image distress, depression, sexual dysfunction not resolving with PT

— Only if history or exam independently suggests abuse — LS findings alone do not mandate report, but inadequate workup of true abuse is malpractice

CCS pearl: Order gynecology referral at the same visit you start clobetasol if exam shows architectural change; document return precautions for new ulcer, bleeding, or non-healing fissure to prompt urgent biopsy.

Board pearl: A non-healing vulvar ulcer in known LS → urgent biopsy and gyn-onc referral, not another steroid trial.

LS is principally outpatient — hospital admission is rare, but recognize when escalation is needed.

Refer to gynecology (or vulvar specialty clinic):

Refer to dermatology:

Refer to gynecologic oncology — urgent:

Refer to urology (men):

Refer to pelvic floor physical therapy:

Refer to mental health / sex therapy:

Child protection services:

Inpatient triage — admit only for surgical complications, severe cellulitis, or postoperative care; LS itself does not require hospitalization.

Key Differentials — Other Vulvar Dermatoses

— Vaginal involvement (erosions, synechiae, stenosis) — LS spares the vagina

— Wickham striae (lacy white reticulation) at edges

— Desquamative inflammatory vaginitis with purulent discharge

— Often involves oral mucosa (gingiva, buccal)

— Key distinction: LP = vaginal + oral; LS = vulvar/perianal, spares vagina

— Itch-scratch cycle → lichenified, thickened, leathery plaques

— No architectural loss, no scarring, no white sclerotic plaque

— Often secondary to underlying LS, eczema, or candidiasis

— Treatment: mid-potency topical steroid, address underlying itch, behavior modification

— History of new product (wipes, soaps, pads, lubricants)

— Erythema, edema, weeping; no white sclerotic change

— Patch testing if recurrent

— Sharply demarcated red, shiny plaques without scale (moist area)

— Look for plaques elsewhere (scalp, nails, umbilicus, gluteal cleft)

— No white scarring

— Postmenopausal, low estrogen

— Vagina pale, thin, friable; vulvar architecture preserved

— Responds to vaginal estrogen; LS does not

— Depigmented patches but normal texture, no atrophy, no itch, no scarring

— Can coexist with LS — biopsy if textural change present

Key distinction (rapid-fire):

— White + scarred + itchy = LS

— White + lacy + vaginal/oral = LP

— White only, no texture change = vitiligo

— Thick + leathery, itch-scratch = LSC

Board pearl: If the vagina is involved (erosions, synechiae, discharge) → it's lichen planus, not LS — the speculum exam is the differentiator.

Lichen planus (LP) — erosive vulvovaginal:

Lichen simplex chronicus (LSC):

Vulvar eczema / contact dermatitis:

Psoriasis (inverse):

Atrophic vaginitis / GSM:

Vitiligo:

Key Differentials — Infections, Neoplasia, and Mimics

— Pruritus, cottage-cheese discharge, erythema; KOH-positive

— Lacks white sclerotic plaques and architectural change

— Commonly co-treated and falsely "diagnosed" in LS patients — beware

— Painful grouped vesicles → erosions; recurrent, prodromal tingling

— PCR/culture confirms; not a chronic white-plaque disease

— Primary: painless chancre

— Secondary: condyloma lata, mucous patches

— Serology (RPR/treponemal) when suspected

— Tense bullae, erosions; DIF biopsy with linear IgG/C3 at BMZ

— Older patients, may involve oral/ocular mucosa

— Recurrent painful vulvar/oral ulcers, uveitis, pathergy

— Linear "knife-cut" perineal/perianal fissures, granulomatous plaques; GI symptoms

— Usual VIN (uVIN) — HPV-16/18, younger women, multifocal warty/basaloid lesions

— Differentiated VIN (dVIN) — LS-associated, older, unifocal, high invasion risk

— Biopsy any suspicious lesion

— Erythematous, eczematous, well-demarcated plaque with white scale; chronic, refractory to steroids

— Biopsy mandatory; rule out underlying adenocarcinoma

— Bruising, fissures, dysuria can overlap with LS; figure-8 white plaques favor LS

— Both can coexist — never let LS diagnosis preclude appropriate abuse evaluation when independently indicated

Key distinction: Steroid-refractory "eczema" of the vulva in any adult → biopsy for Paget disease, dVIN, or SCC before escalating empirical therapy.

Board pearl: Chronic vulvar plaque + crusting + itch unresponsive to clobetasol in an elderly woman = extramammary Paget until biopsy proves otherwise.

Candidal vulvovaginitis:

Herpes simplex virus:

Syphilis (primary or secondary):

Bullous pemphigoid / mucous membrane pemphigoid:

Behçet disease:

Crohn disease (metastatic / cutaneous):

Vulvar intraepithelial neoplasia (VIN) / SCC:

Extramammary Paget disease:

Sexual abuse (pediatric mimic):

Long-Term Plan, Maintenance, and Secondary Prevention

— Proactive clobetasol 0.05% ointment 1–2 times weekly indefinitely OR step-down mid-potency steroid 1–2x/week

— Studies show proactive maintenance reduces relapse, preserves architecture, and may reduce vulvar SCC risk vs. reactive use

— Calcineurin inhibitor (tacrolimus 0.1%) 2–3x weekly as steroid-sparing alternative for selected patients

— Daily plain water cleansing; pat dry

— Petrolatum/zinc oxide barrier after voiding and at bedtime

— Cotton underwear, loose clothing

— Avoid soaps, wipes, scented products, panty liners (except menses)

— Treat incontinence (pelvic floor PT, topical therapy, scheduled voiding) to remove Koebner trigger

— Water-based or silicone lubricants for intercourse

— Vaginal dilators if introital narrowing

— Pelvic floor PT referral for persistent dyspareunia

— Vaginal estrogen for concurrent GSM

— Lifelong clinical vulvar exam every 6–12 months

— Patient self-exam monthly with hand mirror — teach what new lesions look like; provide written handout

— Photograph baseline architecture if feasible

— TSH annually or as symptoms dictate

— Vitamin B12, A1c, celiac serology if symptomatic

— Address steroid phobia at every visit — major driver of under-treatment

— Demonstrate application with mirror at follow-up

— Use fingertip unit / pea-sized measurement; track tube use

Step 3 management: At each visit, ask the "3 questions" — Are you using your clobetasol? How often this month? Any new spots that didn't heal in 4 weeks? — these capture adherence and red flags efficiently.

Board pearl: Stopping maintenance steroid because the patient "looks better" is the #1 cause of relapse and progressive scarring — counsel that LS is lifelong, like hypertension.

Maintenance pharmacotherapy:

Skin care discharge checklist:

Sexual health:

Cancer prevention measures:

Coexisting autoimmune screening:

Adherence support:

Follow-Up, Monitoring Parameters, and Counseling Cadence

— 3 months after starting therapy — assess symptom response, adherence, side effects, re-examine for any non-responding area (biopsy candidate)

— 6 months — confirm maintenance regimen, reinforce skin care, review TSH if not done

— Every 6–12 months thereafter for life — clinical exam, surveillance for malignancy, address sexual/psychological function

— Symptom score — itch, soreness, dyspareunia (0–10 scales useful)

— Skin findings — color, texture, fissures, hyperkeratosis, suspicious lesions

— Architecture — labial resorption, clitoral hood fusion, introital caliber (compare to photographs/notes)

— Steroid use — tubes per month; adherence; technique

— Side effects — atrophy, telangiectasia, candida, contact reaction

— Sexual function and mood — directly ask; offer pelvic PT and counseling referrals

— LS is chronic, controllable but not curable

— Daily/maintenance treatment prevents flares and scarring

— Cancer surveillance is lifelong; biopsy new non-healing lesions

— Skin care matters — gentle, dry, barrier

— Sexual and emotional health are part of treatment — speak up

— New ulcer, fissure, nodule, or pigmented lesion not healing in 4 weeks

— Worsening pain, bleeding, or change in stream/defecation

— Side effects of therapy

— Pelvic floor PT for retained dyspareunia

— Smoking cessation (smoking → vulvar SCC risk)

— Weight management if obesity contributing to moisture/incontinence

Step 3 management: Build a chronic care template — visit every 6 months with itch score, exam findings, steroid tubes/month, and surveillance plan documented; this is a longitudinal Family Med scenario.

Board pearl: Three months of clobetasol → if exam not normalized, biopsy any persistent area before escalating dose.

Visit cadence:

What to monitor at each visit:

Patient counseling pillars (the "5 lifelong messages"):

When to bring patient back sooner:

Rehab and lifestyle:

Ethical, Legal, and Patient Safety Considerations

— Vulvar bruising, fissures, and dysuria in a prepubertal girl can be either LS, abuse, or both coexisting

— Recognize classic figure-8 white sclerotic plaques as LS; this finding alone does not mandate a CPS report

— However, history elements (disclosure, inconsistent caregiver account, behavioral red flags) trigger mandatory reporting independent of LS findings

— Document exam meticulously (photographs with appropriate consent, diagrams); consult child protection / pediatric SANE if any ambiguity — err on the side of evaluation, not silence

— Counsel on expected benefits, side effects (atrophy, telangiectasia, candidiasis), need for indefinite use, and risks of non-treatment (scarring, cancer)

— Address steroid phobia explicitly; provide written materials

— Document discussion of lifetime SCC risk and surveillance plan

— Risks (bleeding, infection, scar, pain), benefits (rule out cancer), alternatives (empiric therapy with close follow-up)

— For minors — parental consent + age-appropriate assent

— Always offer a chaperone for vulvar exam regardless of gender concordance; document offer and acceptance/decline

— Use trauma-informed exam techniques; allow patient control of pace

— Pediatric → adult care: ensure active handoff to gynecology or family medicine with documented diagnosis, treatment history, and surveillance plan — pediatric LS is frequently "lost" at transition and progresses untreated

— Postpartum: re-engage in care after delivery

— Clobetasol ointment is inexpensive and generic — confirm formulary; verify patient can afford and access refills

— Address language and literacy barriers in self-care instructions

— Photographs (with consent), exam diagrams, biopsy results, surveillance plan, and patient acknowledgment of cancer risk

Board pearl: A 5-year-old with vulvar bruising and white plaques → diagnose LS, treat with clobetasol, and independently assess for abuse if history warrants; the two are not mutually exclusive and missing either is a serious failure.

Pediatric LS vs. suspected abuse — the central dilemma:

Informed consent for long-term topical steroid:

Biopsy consent:

Sexual function and chaperone practices:

Transition-of-care risks:

Health equity / access:

Documentation for medicolegal protection:

High-Yield Associations and Rapid-Fire Clinical Facts

— Hashimoto thyroiditis (most common)

— Vitiligo

— Alopecia areata

— Pernicious anemia / B12 deficiency

— Type 1 diabetes

— Also: morphea, celiac, lupus

Board pearl: Three exam buzzwords = "porcelain-white plaque," "figure-8 distribution," "loss of labia minora/clitoral phimosis" — all point to LS.

Key distinction: LS spares the vagina; LP involves it — speculum exam is the decider.

Demographics — bimodal: prepubertal girls + postmenopausal women; F:M ~10:1 in genital disease.

Associated autoimmune conditions (memorize top 5):

Genetic — HLA-DQ7, familial clustering in ~10–15%.

Triggers — Koebner phenomenon (trauma, friction, incontinence, radiation, prior scar).

Classic distribution — figure-8/hourglass: vulva + perianal; spares vagina and cervix.

Histology — hyalinized upper dermal collagen + epidermal atrophy + lymphocytic band + hyperkeratosis with follicular plugging.

First-line therapy — clobetasol 0.05% ointment at every age.

Maintenance — 1–2x weekly indefinitely, proactive > reactive.

Cancer risk — vulvar SCC ~4–5% lifetime, via differentiated VIN (dVIN), HPV-independent, p53-mutated.

Surveillance — clinical vulvar exam every 6–12 months for life; biopsy any non-healing lesion.

Surgery — for complications (introital stenosis, clitoral phimosis, phimosis in men) and cancer, not for inflammation; circumcision often curative for male LS.

Pregnancy — clobetasol safe; vaginal delivery generally okay.

Pediatrics — clobetasol is first-line and safe; ⅔ persist into adulthood — transition care.

Differentials shortlist — lichen planus (vagina/oral), lichen simplex (lichenified), vitiligo (no atrophy), atrophic vaginitis (vagina, no scar), Paget (eczematous, refractory), dVIN/SCC (ulcer/nodule).

Adherence killer — steroid phobia → under-treatment → scarring/cancer.

Common pitfalls — treating as candidiasis, using cream instead of ointment, low-potency steroid alone, stopping therapy when "looks better."

Board Question Stem Patterns

— 62-year-old woman, vulvar itching for 8 months, multiple courses of fluconazole without relief; exam shows white, atrophic figure-8 plaques and resorption of labia minora; PMH Hashimoto.

— Answer: Lichen sclerosus → clobetasol 0.05% ointment

— Distractors: nystatin, vaginal estrogen, oral fluconazole, oral antihistamines

— 6-year-old girl with vulvar bruising, painful defecation, dysuria; exam shows perianal and vulvar white plaques in figure-8; no history suggestive of abuse.

— Answer: Lichen sclerosus → topical clobetasol; CPS report not mandated by exam findings alone

— Distractors: mandatory CPS report, hydrocortisone 1%, oral antifungal, behavioral therapy

— Woman with known LS on clobetasol develops a persistent ulcerated nodule on the labium not healing after 6 weeks.

— Answer: Vulvar biopsy → rule out dVIN/SCC

— Distractors: increase clobetasol potency, add antifungal, MRI pelvis

— 55-year-old man with progressive inability to retract foreskin, whitening of glans, weak stream.

— Answer: LS (BXO) → topical clobetasol first; circumcision if refractory; send specimen to pathology

— Erosive vaginitis with synechiae, oral lacy plaques.

— Answer: Lichen planus, not LS

— LS controlled medically, but introital narrowing prevents intercourse.

— Answer: Refer for perineoplasty, continue maintenance steroid, add dilators/pelvic PT

— New LS diagnosis, fatigue and weight gain.

— Answer: Check TSH for Hashimoto

Step 3 management: When a stem describes "refractory candidiasis" or "abuse mimic" with white plaques and architectural change, the answer is LS + ultrapotent topical steroid — and consider biopsy if anything fails to clear in 3 months.

Board pearl: "Non-healing vulvar lesion in known LS" → the answer is always biopsy.

Classic stem 1 — Postmenopausal pruritus:

Classic stem 2 — Pediatric "abuse" mimic:

Classic stem 3 — Refractory or transforming lesion:

Classic stem 4 — Adult acquired phimosis:

Classic stem 5 — Distinguishing LS from LP:

Classic stem 6 — Architectural complication:

Classic stem 7 — Associated autoimmune workup:

One-Line Recap

Lichen sclerosus is a chronic autoimmune-associated dermatosis of vulvar/perianal (and male genital) skin that causes itch and progressive scarring, is diagnosed clinically with biopsy for atypical or refractory lesions, treated lifelong with proactive ultrapotent topical steroids (clobetasol 0.05% ointment), and surveilled every 6–12 months for the 4–5% lifetime risk of HPV-independent, p53-driven vulvar squamous cell carcinoma arising via differentiated VIN.

Board pearl: LS = chronic, lifelong, steroid-controlled, cancer-surveilled — under-treatment is the enemy, and clobetasol is the answer.

Diagnosis — Clinical hallmarks: porcelain-white, figure-8 plaques with architectural loss (labial resorption, clitoral phimosis, introital stenosis); vagina is spared (distinguishing from lichen planus). Biopsy when atypical, refractory at 3 months, or suspicious for neoplasia; histology shows hyalinized upper dermal collagen + epidermal atrophy + lymphocytic band.

Treatment — Clobetasol 0.05% ointment at every age (children, pregnancy, elderly, men) — induction nightly × 4 weeks, taper to alternate nights × 4 weeks, twice weekly × 4 weeks, then proactive maintenance 1–2x weekly for life; calcineurin inhibitors as steroid-sparing second line; surgery only for complications and cancer.

Surveillance — Lifelong clinical vulvar exam every 6–12 months; biopsy any non-healing erosion, ulcer, nodule, or pigmented lesion to detect dVIN/SCC; screen for associated Hashimoto, vitiligo, T1DM with TSH and clinical exam.

Pitfalls to avoid — Misdiagnosing as candidiasis, using cream over ointment, low-potency steroids, stopping maintenance when "better," confusing pediatric LS with abuse (and vice versa), and forgetting that adult acquired phimosis in men is LS until proven otherwise.